Flippin Bruce & Porter Inc. lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.2% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 33,830 shares of the medical research company’s stock after buying an additional 1,675 shares during the quarter. Flippin Bruce & Porter Inc.’s holdings in Amgen were worth $5,827,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of AMGN. PGGM Investments lifted its position in Amgen by 2.3% in the 2nd quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock valued at $115,555,000 after purchasing an additional 15,059 shares during the last quarter. Shelton Capital Management lifted its position in Amgen by 82.7% in the 1st quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock valued at $17,883,000 after purchasing an additional 49,354 shares during the last quarter. Greylin Investment Mangement Inc. lifted its position in Amgen by 466.9% in the 2nd quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock valued at $2,416,000 after purchasing an additional 11,555 shares during the last quarter. Kelman Lazarov Inc. lifted its position in Amgen by 8.2% in the 2nd quarter. Kelman Lazarov Inc. now owns 1,580 shares of the medical research company’s stock valued at $272,000 after purchasing an additional 120 shares during the last quarter. Finally, Osborne Partners Capital Management LLC lifted its position in Amgen by 0.5% in the 2nd quarter. Osborne Partners Capital Management LLC now owns 17,023 shares of the medical research company’s stock valued at $2,932,000 after purchasing an additional 91 shares during the last quarter. Institutional investors own 78.20% of the company’s stock.
In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $185.95, for a total transaction of $283,573.75. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Carbonnel Francois De sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Insiders have sold 7,050 shares of company stock worth $1,239,673 over the last ninety days. 0.19% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2017/11/15/flippin-bruce-porter-inc-acquires-1675-shares-of-amgen-inc-amgn-2.html.
Amgen Inc. (NASDAQ AMGN) opened at $170.13 on Wednesday. Amgen Inc. has a 1 year low of $138.83 and a 1 year high of $191.10. The firm has a market cap of $124,493.66, a P/E ratio of 13.63, a PEG ratio of 2.48 and a beta of 1.37. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The firm had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. During the same period in the previous year, the firm posted $3.02 earnings per share. The firm’s revenue was down .7% on a year-over-year basis. research analysts predict that Amgen Inc. will post 12.66 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Friday, November 17th will be given a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a yield of 2.70%. The ex-dividend date of this dividend is Thursday, November 16th. Amgen’s payout ratio is presently 41.63%.
Amgen announced that its board has initiated a share buyback plan on Wednesday, October 25th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.
Several analysts recently weighed in on AMGN shares. Cann reiterated a “buy” rating and issued a $203.00 price objective (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $203.00 price objective on shares of Amgen in a research report on Thursday, September 7th. Mizuho reiterated a “buy” rating and issued a $183.00 price objective (down from $195.00) on shares of Amgen in a research report on Monday, August 21st. BidaskClub downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Argus boosted their price target on shares of Amgen from $180.00 to $195.00 and gave the stock a “buy” rating in a research report on Thursday, July 27th. Thirteen analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $190.03.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.